Lithium Ion

Lithium Ion

SCHEMBL1136822

COc1cccc([O-])c1C.[Li+]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
CA7 P43166 3/20 0.46
CA9 Q16790 3/20 0.46
CA12 O43570 2/20 0.46
CA14 Q9ULX7 2/20 0.46
CA4 P22748 1/20 0.46
ALDH1A1 P00352 5/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 2/20 0.41
MAPK1 P28482 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ENPP2 Q13822 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146841 0.80 CA1 (0.61) CA1CA2CA7CA9CA12
Guaiacol SCHEMBL3288239 0.78 CA1 (0.60) CA1CA2CA7CA9CA12
Boric Acid SCHEMBL5237071 0.76 ENPP2 (0.54) CA1CA2CA7CA9CA12
Syringol SCHEMBL6049239 0.75 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL78554 0.73 CA1 (0.52) CA1CA2CA7CA9CA12
SCHEMBL7921177 0.73 CA1 (0.52) CA1CA2CA7CA9CA12
SCHEMBL29352478 0.73 CA1 (0.52) CA1CA2CA7CA9CA12
Guaiacol SCHEMBL678968 0.73 CA1 (0.60) CA1CA2CA7CA9CA12
SCHEMBL28575044 0.73 CA1 (0.52) CA1CA2CA7CA9CA12
Guaiacol SCHEMBL9363005 0.73 CA1 (0.60) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651690-B1 PROCESS FOR THE PREPARATION OF A POLYOLEFIN LANXESS ELASTOMERS BV (NL) 2015-07-01 EP disclosed
EP-1651686-B1 IMPROVED METHOD OF PREPARING A HYDROCARBYLATED METAL-ORGANIC COMPOUND LANXESS ELASTOMERS BV (NL) 2013-10-16 EP disclosed
EP-1730205-B1 POLIMERIZATION CATALYST COMPRISING AN AMIDINE LIGAND LANXESS ELASTOMERS BV (NL) 2012-09-26 EP disclosed
US-7956140-B2 Polymerization catalyst comprising amidine ligand DSM IP ASSETS B.V. (NL) 2011-06-07 US disclosed
EP-1781716-B1 PROCESS FOR THE PREPARATION OF A POLYMER DSM IP ASSETS BV (NL) 2011-02-23 EP disclosed
US-7816548-B2 Method of preparing a hydrocarbylated metal-organic compound DSM IP ASSETS B.V. (NL) 2010-10-19 US disclosed
US-7547751-B2 Process for the preparation of a polyolefin DSM IP ASSETS B.V. (NL) 2009-06-16 US disclosed
US-20090043060-A1 Process For the Preparation of a Polymer DSM IP ASSETS B.V. (NL) 2009-02-12 US disclosed
US-20090012246-A1 Polymerization Catalyst Comprising Amidine Ligand DMS IP ASSETS B.V. (NL) 2009-01-08 US disclosed
US-20080153999-A1 Polymerization of at least one aliphatic or aromatic hydrocarbyl C2-20 mono- or multiolefin in the presence of a catalyst and a boron comprising co-catalyst, wherein the catalyst comprises of a metal-organic reagent, a spectator ligand and optionally at least one equivalent of a hydrocarbylting agent ARLANXEO NETHERLANDS B.V. (NL) 2008-06-26 US disclosed
US-20060252893-A1 Process for the preparation of a polyolefin ARLANXEO NETHERLANDS B.V. (NL) 2006-11-09 US disclosed
EP-1651690-A2 PROCESS FOR THE PREPARATION OF A POLYOLEFIN DSM IP Assets B.V. (NL) 2006-05-03 EP disclosed
EP-1651691-A2 PROCESS FOR THE PREPARATION OF A POLYOLEFIN DSM IP Assets B.V. (NL) 2006-05-03 EP disclosed
EP-1651686-A1 IMPROVED METHOD OF PREPARING A HYDROCARBYLATED METAL-ORGANIC COMPOUND DSM IP Assets B.V. (NL) 2006-05-03 EP disclosed
WO-2005123790-A1 PROCESS FOR THE PREPARATION OF A POLYMER DSM IP ASSETS B.V. (NL) 2005-12-29 WO disclosed
WO-2005090418-A1 POLIMERIZATION CATALYST COMPRISING AN AMIDINE LIGAND DSM IP ASSETS B.V. (NL) 2005-09-29 WO disclosed
EP-1535936-A1 Improved method of preparing a hydrocarbylated metal-organic compound DSM IP Assets B.V. (NL) 2005-06-01 EP disclosed
WO-2005014601-A2 PROCESS FOR THE PREPARATION OF A POLYOLEFIN DSM IP ASSETS B.V. (NL) 2005-02-17 WO disclosed
WO-2005014669-A1 IMPROVED METHOD OF PREPARING A HYDROCARBYLATED METAL-ORGANIC COMPOUND DSM IP ASSETS B.V. (NL) 2005-02-17 WO disclosed
WO-2005014674-A2 PROCESS FOR THE PREPARATION OF A POLYOLEFIN DSM IP ASSETS B.V. (NL) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012246-A1 Polymerization Catalyst Comprising Amidine Ligand AP2M1, SNW1, BZW1 CA1 3187/4885CA2 3922/4885CA7 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.